The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2025
PET imaging and radionuclide therapy in neuroendocrine prostate cancer: a systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdlkadir Ahmed S, Al-Adhami Dhuha, Al-Rasheed Ula, Jreige Mario, Mahafza Waleed, Al-Khawaldeh Khaled, Estrada-Lobato Enrique, Al-Ibraheem Akram
Аннотация
INTRODUCTION: Neuroendocrine prostate cancer (NEPC) is a rare cancer subtype with significant prognostic implications. This systematic review aims to explore the current landscape of positron emission tomography (PET) imaging and radionuclide therapy in this rare entity.
EVIDENCE ACQUISITION: The Scopus and PubMed online databases were systemically reviewed to identify relevant studies on the topic of interest.
EVIDENCE SYNTHESIS: A total of 60 studies reporting such evidence in 102 patients were retrieved. A total of 179 PET/CT examinations were performed across all NEPC patients, with [18F]Fluorodeoxyglucose ([18F]FDG) being the most frequently utilized radiotracer (45% of NEPC patients), followed by [68Ga]Ga-DOTA-peptides (22%), [68Ga]Ga-prostate specific membrane antigen ([68Ga]Ga-PSMA) (18%), and other PET tracers (15%). Single-modality PET/CT imaging was mostly employed to evaluate NEPC extent, detect unusual metastatic sites, assess therapy response, and guide for biopsy sites in cases of hormone-secreting NEPC. Multimodal PET/CT utilizing dual- or triple-tracer approaches was employed for collective NEPC interpretation, assessment of heterogeneity, therapy response assessment, and determination of radionuclide therapy eligibly. For treatment, 16 [177Lu]Lu-DOTATATE cycles, administered to 7 patients, produced effective disease control in all patients. One patient received both [177Lu]Lu-PSMA and [177Lu]Lu-DOTATATE, achieving partial response, while another patient receiving 4 [177Lu]Lu-PSMA cycles also showed a partial response.
CONCLUSIONS: The multimodal molecular imaging approach appears to be the most effective for NEPC evaluation and determination of radionuclide therapy eligibility. [177Lu]Lu-based therapies seem to be a compelling treatment approach to be pursued in eligible cases, although larger studies are needed to confirm the current findings.
EVIDENCE ACQUISITION: The Scopus and PubMed online databases were systemically reviewed to identify relevant studies on the topic of interest.
EVIDENCE SYNTHESIS: A total of 60 studies reporting such evidence in 102 patients were retrieved. A total of 179 PET/CT examinations were performed across all NEPC patients, with [18F]Fluorodeoxyglucose ([18F]FDG) being the most frequently utilized radiotracer (45% of NEPC patients), followed by [68Ga]Ga-DOTA-peptides (22%), [68Ga]Ga-prostate specific membrane antigen ([68Ga]Ga-PSMA) (18%), and other PET tracers (15%). Single-modality PET/CT imaging was mostly employed to evaluate NEPC extent, detect unusual metastatic sites, assess therapy response, and guide for biopsy sites in cases of hormone-secreting NEPC. Multimodal PET/CT utilizing dual- or triple-tracer approaches was employed for collective NEPC interpretation, assessment of heterogeneity, therapy response assessment, and determination of radionuclide therapy eligibly. For treatment, 16 [177Lu]Lu-DOTATATE cycles, administered to 7 patients, produced effective disease control in all patients. One patient received both [177Lu]Lu-PSMA and [177Lu]Lu-DOTATATE, achieving partial response, while another patient receiving 4 [177Lu]Lu-PSMA cycles also showed a partial response.
CONCLUSIONS: The multimodal molecular imaging approach appears to be the most effective for NEPC evaluation and determination of radionuclide therapy eligibility. [177Lu]Lu-based therapies seem to be a compelling treatment approach to be pursued in eligible cases, although larger studies are needed to confirm the current findings.